Phase II with Multiple Subgroups: Designs Incorporating Disease Subtype or Genetic Heterogeneity

Authored by: Michael LeBlanc , Cathryn Rankin , John J. Crowley

Handbook of Statistics in Clinical Oncology

Print publication date:  March  2012
Online publication date:  March  2012

Print ISBN: 9781439862001
eBook ISBN: 9781439862018
Adobe ISBN:

10.1201/b11800-14

 Download Chapter

 

Abstract

Patients registered to a Phase II study often are heterogeneous and may not be expected to respond equally to a new treatment. Tumors can consist of multiple sub-types diagnosed either histologically or by molecular methods. For example, soft tissue sarcomas or non-Hodgkin lymphomas have multiple subtypes that can be identified by microscopic inspection of the tumor sample. Similarly, newer genomic measurements such as gene expression or comparative genomic hybridization on these tumors can now lead to refinement or regrouping of patients for clinical studies. For instance, expression of measures of HER2, EGFR, VEGF may influence the expectation of response by certain drugs in some tumors. While we are specifically interested in Phase II studies in oncology, our ideas relate more broadly to the use of biomarker or subtype information in the design of clinical experiments.

 Cite
Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.